Head-to-head evidence
Paliperidone palmitate (Invega Sustenna) vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: June 2028 · NCT05603104 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Invega Sustenna)'s landscape · Quetiapine (Seroquel)'s landscape